Disclosures for "The Canadian Registry for Amyloidosis Research: A national multi-disciplinary registry for real-world evidence")
-
Dr. Massie has received personal compensation in the range of $500-$4,999 for serving as a Expert consultant with INESS (Quebec Public Health agency). Dr. Massie has received personal compensation in the range of $500-$4,999 for serving as a Lecturer with Amylyx Pharmaceuticals.
-
Diego Delgado has nothing to disclose.
-
Dr. Venner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen.
-
Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Bril has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Akcea. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Bril has received research support from UCB. The institution of Dr. Bril has received research support from Argenx. The institution of Dr. Bril has received research support from Momenta. The institution of Dr. Bril has received research support from Immunovant. The institution of Dr. Bril has received research support from Alexion. The institution of Dr. Bril has received research support from Takeda. Dr. Bril has received intellectual property interests from a discovery or technology relating to health care.
-
Donna Reece has nothing to disclose.
-
Dr. Baker has nothing to disclose.
-
Victoria Hodgkinson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe Pharma. Victoria Hodgkinson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dynacure. Victoria Hodgkinson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Victoria Hodgkinson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.
-
Ms. Boyartchuk has nothing to disclose.
-
Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrazeneca/Ionis. Dr. Davis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Davis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Janssen. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer.
-
Nowell Fine has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of the American College of Cardiology: Case Reports. The institution of Nowell Fine has received research support from Pfizer, Akcea.